BE2019C533I2 - - Google Patents

Info

Publication number
BE2019C533I2
BE2019C533I2 BE2019C533C BE2019C533C BE2019C533I2 BE 2019C533 I2 BE2019C533 I2 BE 2019C533I2 BE 2019C533 C BE2019C533 C BE 2019C533C BE 2019C533 C BE2019C533 C BE 2019C533C BE 2019C533 I2 BE2019C533 I2 BE 2019C533I2
Authority
BE
Belgium
Application number
BE2019C533C
Other languages
Dutch (nl)
Original Assignee
Shionogi & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co Ltd filed Critical Shionogi & Co Ltd
Publication of BE2019C533I2 publication Critical patent/BE2019C533I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2019C533C 2005-05-25 2019-06-24 BE2019C533I2 (enExample)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005151864 2005-05-25
JP2006065762 2006-03-10
PCT/JP2006/310231 WO2006126529A1 (ja) 2005-05-25 2006-05-23 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
PCT/JP2006/310454 WO2006126637A1 (ja) 2005-05-25 2006-05-25 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体

Publications (1)

Publication Number Publication Date
BE2019C533I2 true BE2019C533I2 (enExample) 2025-12-10

Family

ID=37451954

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2019C533C BE2019C533I2 (enExample) 2005-05-25 2019-06-24

Country Status (20)

Country Link
US (4) USRE46365E1 (enExample)
EP (1) EP1889848B8 (enExample)
JP (1) JP4323547B2 (enExample)
KR (1) KR100912782B1 (enExample)
CN (1) CN101228172B (enExample)
AU (1) AU2006250390B2 (enExample)
BE (1) BE2019C533I2 (enExample)
BR (1) BRPI0610343B8 (enExample)
CA (1) CA2609733C (enExample)
DK (1) DK1889848T3 (enExample)
ES (1) ES2525215T3 (enExample)
FR (1) FR19C1042I2 (enExample)
HU (1) HUS1900034I1 (enExample)
MX (1) MX2007014588A (enExample)
NL (1) NL300996I2 (enExample)
PL (1) PL1889848T3 (enExample)
PT (1) PT1889848E (enExample)
RU (1) RU2403255C2 (enExample)
TW (1) TWI311056B (enExample)
WO (2) WO2006126529A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
CA3066426A1 (en) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
JP5252391B2 (ja) * 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ[2.2.2]オクタンを有するモルヒナン誘導体およびその医薬用途
CA2734333A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
WO2011035142A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
WO2011142620A2 (en) * 2010-05-13 2011-11-17 Green Cross Corporation (+)-3-hydroxymorphinan-based polycycle derivatives as neuroprotectants
AU2011327113B9 (en) 2010-11-12 2015-07-30 Shionogi & Co., Ltd. Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
US10952968B2 (en) 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
EP3560487A4 (en) 2016-12-26 2020-07-29 Shionogi & Co., Ltd. PRODUCTION METHOD FOR FORMULATION WITH IMPROVED UNIFORMITY OF CONTENT
WO2019200202A1 (en) 2018-04-12 2019-10-17 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
KR102201609B1 (ko) 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
MX2022004406A (es) 2019-10-16 2022-08-25 Morphic Therapeutic Inc INHIBICIÓN DE INTEGRINA A4ß7 HUMANA.
JP7582961B2 (ja) 2019-11-20 2024-11-13 塩野義製薬株式会社 6,7-不飽和-7-カルバモイルモルヒナン誘導体含有固形製剤
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
IT202300009864A1 (it) 2023-05-16 2024-11-16 Procos Spa Processo per la preparazione di naldemedina

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4275205A (en) * 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) * 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) * 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) * 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
EP0663401B1 (en) * 1993-07-23 2000-06-07 Toray Industries, Inc. Morphinan derivative and medicinal use
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
KR19990077125A (ko) 1996-01-10 1999-10-25 파올로 비지, 엔리꼬 카쭐라니 헤테로고리-축합 모르핀 유도체 (ⅱ)
AU5891600A (en) 1999-07-01 2001-01-22 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
WO2001037785A2 (en) * 1999-11-29 2001-05-31 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
CA2408106A1 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
AU2001259560B2 (en) 2000-05-05 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
ES2304477T3 (es) * 2000-10-31 2008-10-16 Rensselaer Polytechnic Institute Procedimiento de preparacion de compuestos con afinidad a receptores opioides.
CA2427931A1 (en) * 2000-11-22 2002-05-30 Toray Industries, Inc. Indole derivatives and medical applications thereof
KR100901402B1 (ko) * 2001-08-23 2009-06-05 엔.브이.오가논 14-히드록시노르모르피논 유도체의 제조 방법
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
CN1288158C (zh) * 2002-07-11 2006-12-06 东丽株式会社 用于预防恶心和呕吐的治疗剂或预防剂
AU2003299045A1 (en) 2002-09-18 2004-04-08 The Curators Of The University Of Missouri OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR
US20040157784A1 (en) * 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
EP1758452B1 (en) 2004-05-28 2017-01-25 Human Biomolecular Research Institute Metabolically stable analgesics and pain medications
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
AU2011327113B9 (en) 2010-11-12 2015-07-30 Shionogi & Co., Ltd. Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same

Also Published As

Publication number Publication date
CA2609733A1 (en) 2006-11-30
BRPI0610343B8 (pt) 2021-05-25
USRE46365E1 (en) 2017-04-11
WO2006126529A1 (ja) 2006-11-30
TW200726470A (en) 2007-07-16
PL1889848T3 (pl) 2015-04-30
US20090203723A1 (en) 2009-08-13
DK1889848T3 (en) 2014-12-01
RU2403255C2 (ru) 2010-11-10
CN101228172A (zh) 2008-07-23
EP1889848B1 (en) 2014-10-15
US8536192B2 (en) 2013-09-17
WO2006126637A1 (ja) 2006-11-30
CA2609733C (en) 2011-07-19
AU2006250390B2 (en) 2010-07-08
EP1889848B8 (en) 2014-12-17
TWI311056B (en) 2009-06-21
BRPI0610343A2 (pt) 2010-06-15
JP4323547B2 (ja) 2009-09-02
FR19C1042I2 (fr) 2020-06-19
EP1889848A1 (en) 2008-02-20
PT1889848E (pt) 2014-12-09
FR19C1042I1 (enExample) 2019-08-09
CN101228172B (zh) 2013-04-03
US20120135978A1 (en) 2012-05-31
NL300996I1 (nl) 2019-07-03
AU2006250390A1 (en) 2006-11-30
HUS1900034I1 (hu) 2019-07-29
RU2007148412A (ru) 2009-06-27
ES2525215T3 (es) 2014-12-19
EP1889848A4 (en) 2011-08-10
KR20080014791A (ko) 2008-02-14
BRPI0610343B1 (pt) 2020-03-10
KR100912782B1 (ko) 2009-08-18
MX2007014588A (es) 2008-01-24
NL300996I2 (nl) 2019-07-30
US8084460B2 (en) 2011-12-27
USRE46375E1 (en) 2017-04-25
JPWO2006126637A1 (ja) 2008-12-25

Similar Documents

Publication Publication Date Title
BE2021C524I2 (enExample)
FR20C1024I1 (enExample)
BE2019C533I2 (enExample)
BE2014C057I2 (enExample)
BE2013C074I2 (enExample)
BE2013C014I2 (enExample)
BE2012C042I2 (enExample)
BRPI0601358B8 (pt) Aplicador de clipe cirúrgico
BRPI0601402B8 (pt) Aplicador de grampos cirúrgicos
BR122017004709A2 (enExample)
JP2006236143A5 (enExample)
JP2006175588A5 (enExample)
BRPI0609157A8 (enExample)
JP2006179887A5 (enExample)
BRPI0608519A2 (enExample)
JP2005277392A5 (enExample)
AP2140A (enExample)
BR122016029989A2 (enExample)
BRPI0604219A (enExample)
JP2006298020A5 (enExample)
JP2006210234A5 (enExample)
BRPI0618215B8 (enExample)
JP2006265792A5 (enExample)
FR2893480B3 (enExample)
CN105122969C (enExample)